Evaluation of the von Willebrand factor Y1584C polymorphism as a potential risk factor for bleeding in patients receiving anticoagulant treatment with vitamin K antagonists
- 1 April 2005
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (4) , 797-798
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Non‐fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IXJournal of Thrombosis and Haemostasis, 2004
- An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13Blood, 2004
- Founder von Willebrand factor haplotype associated with type 1 von Willebrand diseaseBlood, 2003
- High Concentration of Thrombomodulin in Plasma Is Associated With HemorrhageCirculation, 1997
- Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)The Lancet, 1996
- Bleeding Complications in Oral Anticoagulant TherapyArchives of internal medicine (1960), 1993
- Structure of the gene for human von Willebrand factorJournal of Biological Chemistry, 1989